Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Canagliflozin vs Hibiscus: Hibiscus has the stronger overall evidence (6 vs 4.5/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Hibiscus wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
Top outcomes
Verdict
Too few graded studies
Top outcomes
Shared outcomes (2)
Outcomes where both Canagliflozin and Hibiscus have evidence — compare verdict strength side-by-side.
Off-label use mirrors diabetes dosing (e.g. 100–300 mg once daily before the first meal) under a clinician. A prescription drug; not an approved longevity regimen.
Morning
Oral tablet (canagliflozin)
250–450 mg standardized extract OR 1.25–2.5 g dried calyx per serving (as tea)
With meals, 2–3 times daily, Morning and afternoon preferred
Standardized extract capsule (anthocyanins ≥10%)
and 1 more not shown
Weeks
Unknown in humans
Months to years
Weeks to months
4–6 weeks
6–8 weeks
Acute to 2 weeks
4–8 weeks
Canagliflozin extends life span in genetically heterogeneous male but not female mice.
JCI insight (2020) · Animal
NIA Interventions Testing Program: canagliflozin extended lifespan in male mice
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
The New England journal of medicine (2015) · Rct · n=7020
EMPA-REG OUTCOME randomized trial (empagliflozin, same class)
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
The New England journal of medicine (2021) · Rct
EMPEROR-Preserved randomized trial (empagliflozin)
Efficacy and safety of Hibiscus sabdariffa in cardiometabolic health: An overview of reviews and updated dose-response meta-analysis.
Complementary therapies in medicine (2025) · Meta analysis · n=1797
Overview of systematic reviews and updated dose-response meta-analysis confirms cardiometabolic benefits of Hibiscus sabdariffa
A systematic review and meta-analysis of the effects of Hibiscus sabdariffa on blood pressure and cardiometabolic markers.
Nutrition reviews (2022) · Meta analysis
Hibiscus significantly reduced systolic BP by −7.10 mmHg (95%CI −13.00 to −1.20) versus placebo
Efficacy of Hibiscus sabdariffa on Reducing Blood Pressure in Patients With Mild-to-Moderate Hypertension: A Systematic Review and Meta-Analysis of Published Randomized Controlled Trials.
Journal of cardiovascular pharmacology (2022) · Meta analysis · n=1205
13 RCTs (1205 participants) analyzed; hibiscus significantly reduced SBP by −6.67 mmHg and DBP by −4.35 mmHg vs placebo
Hibiscus has a higher evidence score (6/10 vs 4.5/10) and wins in 2 of 3 categories.
For support heart health, Hibiscus has a higher relevance score (75 vs 70).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.